Until recently, no targeted therapy was approved for BTC, until the Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved pemigatinib in 2020 for CCA with an fibroblast growth factor receptor 2 (FGFR2) rearrangement or fusion [33] and ivosidenib in case of isocitrate dehydrogenase 1 (IDH1) mutation [34] for FDA. The gene discussed is FGFR2; the disease is cholangiocarcinoma.